Categories AlphaGraphs, Earnings, Technology
BB Earnings: Highlights of BlackBerry’s Q1 2024 results
BlackBerry Limited (NYSE: BB) has reported a profit for the first quarter of 2024, on an adjusted basis, compared to a loss last year. The tech firm’s revenues more than doubled during the quarter.
Total revenues increased sharply to $373 million in the first quarter from $168 million in the corresponding period of 2023. A sharp increase in Licensing & Other revenue more than offset weakness in the other businesses.
The company reported adjusted earnings of $0.06 per share for the quarter, compared to an adjusted loss of $0.05 per share a year earlier. On an unadjusted basis, it was a net loss of $11 million or $0.02 per share, compared to a loss of $181 million or $0.35 per share in the first quarter of 2023.
“This quarter we delivered sequential revenue growth in our Cybersecurity business unit. Revenue growth was driven by a year-over-year increase in billings and pipeline, anchored on strength in our core verticals, particularly government,” said John Chen, CEO of BlackBerry.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Nike (NKE) looks set to beat hurdles and build a brighter future
Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business
Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company
Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications
